CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 24, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in a second patent application that broadly covers methods for preparing small interfering RNAs (siRNAs), the molecules that mediate RNAi. The USPTO issued a ‘Notice of Allowance’ for patent application 10/832,432 in the ‘Tuschl II’ patent series. Following a ‘Notice of Allowance’, the final issuance of a patent involves several administrative steps that typically are completed within three months.
